Strategy Training for Mild Cognitive Impairment
(ForAging Trial)
Trial Summary
What is the purpose of this trial?
Loss of cognitive abilities leading to Alzheimer's disease is progressive and destructive, leaving older adults disabled and unable to recall their past. The number of older adults with Alzheimer's disease is expected to triple by the year 2050, yet little research examines amyloid beta deposition, executive function, and progression of disability. This study will test the influence of a novel and promising non-pharmacological intervention, Strategy Training, on the progression of disability in a sample of 150 older adults with Mild Cognitive Impairment who have the option to complete a Positron Emission Tomography (PET) Imaging with Pittsburgh Compound B (PiB).
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It might be best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment Strategy Training, Metacognitive Strategy Training for Mild Cognitive Impairment?
Research shows that strategy training can improve memory and executive functions (skills for managing tasks) in older adults with mild cognitive impairment. Studies found that participants who received strategy training had better memory recall and language skills, and reported fewer memory complaints in daily life.12345
Is strategy training safe for humans?
How does the treatment Strategy Training differ from other treatments for mild cognitive impairment?
Strategy Training, also known as Metacognitive Strategy Training, is unique because it focuses on teaching patients to use specific strategies and metacognitive skills (thinking about one's own thinking) to improve decision-making and executive functions, which are crucial for daily activities. Unlike other treatments, it emphasizes analytical thinking and compensatory techniques to enhance memory and attention, showing improvements that can be maintained over time.23456
Research Team
Juleen Rodakowski, OTD,MS,OTR/L
Principal Investigator
University of Pittsburgh
Eligibility Criteria
This trial is for older adults living in the community who have been diagnosed with Mild Cognitive Impairment (MCI) and are noticing difficulties with daily activities. It's not suitable for those with other central nervous system disorders, substance disorders within the last five years, severe psychiatric conditions like bipolar disorder or schizophrenia, untreated major depression, severe medical conditions limiting daily activity, or if pregnant.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Baseline Assessment
Initial assessments including amyloid-beta deposition and neurocognitive function
Strategy Training
Participants engage in 10 sessions over 5 weeks with a trained research interventionist to identify and prioritize activity-based goals
Short-term Follow-up
Assessment of change in disability and cognitive function at 8 weeks post-intervention
Long-term Follow-up
Participants are monitored for safety and effectiveness after treatment, with assessments at 6 and 12 months post-intervention
Treatment Details
Interventions
- Strategy Training
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Pittsburgh
Lead Sponsor
National Institutes of Health (NIH)
Collaborator
National Institute on Aging (NIA)
Collaborator